Thanks gestalt2 for posting that. I encourage everyone to read that article. We need to keep our distance from Patterson. Already, several academic doctors are cited in that article who have significant concerns with the program at IncellDx. We don't need to go there. That being said, the 13Ders were correct that we needed a new CEO and change to the board structure. So with the new CEO search, and board, we have some form of compromise so to speak.

Anyway, I think the company is turning the corner, and I'm increasingly bullish, so long as we stay on top of the financials.

Monoclonal antibodies make billions (keytruda, humira), and I believe Leronlimab will eventually get there. CCR5 as a therapeutic target is involved in countless diseases. We have the best drug out there for that target. Seeing the potential before others do, is where the money is made.